Cogent Biosciences, Inc. - FORM S-1/A - EX-23.1 - March 19, 2018

Attached files

file filename
S-1/A - AMENDMENT NO.1 TO FORM S-1 - Cogent Biosciences, Inc.d416842ds1a.htm
EX-10.13 - EX-10.13 - Cogent Biosciences, Inc.d416842dex1013.htm
EX-10.12 - EX-10.12 - Cogent Biosciences, Inc.d416842dex1012.htm
EX-10.11 - EX-10.11 - Cogent Biosciences, Inc.d416842dex1011.htm
EX-10.10 - EX-10.10 - Cogent Biosciences, Inc.d416842dex1010.htm
EX-10.9 - EX-10.9 - Cogent Biosciences, Inc.d416842dex109.htm
EX-10.8 - EX-10.8 - Cogent Biosciences, Inc.d416842dex108.htm
EX-10.7 - EX-10.7 - Cogent Biosciences, Inc.d416842dex107.htm
EX-10.6 - EX-10.6 - Cogent Biosciences, Inc.d416842dex106.htm
EX-10.5 - EX-10.5 - Cogent Biosciences, Inc.d416842dex105.htm
EX-10.1 - EX-10.1 - Cogent Biosciences, Inc.d416842dex101.htm
EX-5.1 - EX-5.1 - Cogent Biosciences, Inc.d416842dex51.htm
EX-4.3 - EX-4.3 - Cogent Biosciences, Inc.d416842dex43.htm
EX-4.1 - EX-4.1 - Cogent Biosciences, Inc.d416842dex41.htm
EX-3.5 - EX-3.5 - Cogent Biosciences, Inc.d416842dex35.htm
EX-3.4 - EX-3.4 - Cogent Biosciences, Inc.d416842dex34.htm
EX-3.2 - EX-3.2 - Cogent Biosciences, Inc.d416842dex32.htm
EX-1.1 - EX-1.1 - Cogent Biosciences, Inc.d416842dex11.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 of Unum Therapeutics Inc. of our report dated March 2, 2018, except for the effects of the reverse stock split discussed in Note 15 to the consolidated financial statements, as to which the date is March 19, 2018, relating to the financial statements, which appears in such Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

March 19, 2018

Cogent Biosciences, Inc. Reports